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Abstract In the pharmaceutical industry, there are increasing
requirements for analytical methods in quality assessment for
the production of drugs. In this investigation, ion mobility
spectrometry (IMS) was used for the rapid qualitative
separation and identification of active ingredients in generic
over-the-counter drugs and food additives in beverages. The
active ingredients determined in drugs were acetaminophen,
aspartame, bisacodyl, caffeine, dextromethorphan, diphenhy-
dramine, famotidine, glucosamine, guaifenesin, loratadine,
niacin, phenylephrine, pyridoxine, thiamin, and tetrahydrozo-
line. Aspartame and caffeine were determined in beverages.
Fourteen over-the-counter drugs and beverages were ana-
lyzed. Analysis times below 10 s were obtained for IMS, and
reduced mobilities were reported for the first time for 12
compounds. A quadrupole mass spectrometer coupled to a
mobility spectrometer was used to assure a correct peak
assignation. The combination of fast analysis, low cost, and
inexpensive maintenance of IMS instruments makes IMS an
attractive technique for the qualitative determination of the
active ingredients in over-the-counter drugs and food addi-
tives in manufacture quality control and cleaning verification
for the drug and food industries.
Keywords Ionmobilityspectrometry.Over-the-counter
drug.Foodadditive.Sweetener
Introduction
The introduction of modified foods, as well as food, drug,
and cosmetic additives has been a major change in people’s
lives over the past three decades. Food and beverages are
being altered to make them more appetizing and colorful, to
retard spoilage, and to conceal spoiled products. A public
increasingly interested in healthy food and aware of the
health implications of these additives, together with new
revelations from the scientific community on their health
effects, have driven food control institutions to issue
regulations on the use of these chemicals.
There is controversy on the health risks of food additives
(colorings, flavorings, and preservatives). Some authors
claim that artificial sweeteners, such as saccharin, cycla-
mate, and aspartame, do not pose carcinogenic threats [1].
However, other studies show these sweeteners as a human
cancer risk [2, 3]. In addition, it was demonstrated that
some food additives produce allergic responses [4] and
may increase hyperactivity in children with behavior
problems [5, 6].
There is a growing need in the food and pharmaceutical
industries for rapid, low-cost, and sensitive analytical
methods in quality assessment and cleaning verification
for the quality control and production of over-the-counter
drugs and food [1]. A rapid, low-cost, sensitive method is
required for routine screening of batches of raw materials,
the production line, and the final commercial products to
avoid deterioration and changes in specifications. Rapid
cleaning verification is also a challenge related to screening
pharmaceutical components on production equipment to
avoid contamination of future products [7]. The tech-
niques currently used for quality control in the pharmaceu-
tical industry, such as HPLC and total organic carbon
(TOC), are slow and relatively inaccurate [7, 8]. TOC is
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because it finds all organic carbon and cannot distinguish
between excipients or cleaning residues and the active
ingredients. These false indications are nonexistent in IMS,
which gives quantitative, selective results [7, 9]
HPLC is a selective and popular analytical method for
the determination of over-the counter-drugs and food
additives, but it is very expensive and the analysis times
are between 1 and 20 min [10, 11]. In contrast, IMS can
develop analysis run times of about 20–45 ms, and lab-
made IMS instruments can be assembled at low cost.
Besides, the cost of maintenance of IMS instruments is
much lower than that of HPLC. With IMS, cost savings are
realized in two areas: costs of consumables (solvents and
column materials) needed in HPLC and cost savings found
in the IMS’s speed [7]. Other techniques such as gas
chromatography (GC) also suffer several shortcomings,
namely, lengthy analysis times and use of solvents. An
advantage of IMS over HPLC or GC is the absence of
analysis problems associated with faulty or dirty columns.
Moreover, IMS instruments are easy to use, as demonstrat-
ed by their widespread employment in military and aviation
security applications.
Ion mobility spectrometry (IMS), introduced by the end
of the 60’s by Cohen and Karasek [12], is an analytical
technique that separates gas-phase ions at atmospheric
pressure. IMS is a fast, low-cost, and sensitive method
ideal for the detection of trace quantities of volatile organic
and inorganic compounds. The main applications of early
IMS instruments were the detection of illegal drugs [13],
explosives [14], and chemical warfare agents [15]. The
introduction of electrospray ionization–ion mobility spec-
trometry (ESI-IMS) in the late 1980’s allowed the easy
analyses of non-volatile and labile samples [16]. The
combination of ion mobility spectrometers with mass
spectrometers permitted analysis of metabolomes [17] and
proteomes [18], study of protein-protein and noncovalent
protein-ligand complexes [19], imaging of tissues [20], and
separation of carbohydrate isomers [21] and mixtures of
peptides [22].
In an ion mobility spectrometer, samples are ionized at
atmospheric pressure, and an electric field drives the ions
through a drift tube where collisions occur between the ions
and neutral buffer gas molecules. Ionization commonly
occurs by a radioactive, electrospray, or corona discharge
source. After ionization, the ions are focused into a drift
tube composed of a desolvation and a drift region. In the
desolvation region, ions are stripped of solvent molecules
with the help of a preheated counter-current of neutral gas
(the buffer gas), and pulsed into the drift region by an ion
gate. The ions are then accelerated through the drift region
by the electric field, where they obtain a constant drift
velocity. This constant velocity (v, cm s
−1), proportional to
the electric field (E, cm
2s
−1), results from the accelerating
electric field and the retarding effect of random collisions
with the gas [23]:
K ¼
v
E
¼
L2
V:td
ð1Þ
where L is the length of the drift region in cm, V the total
voltage drop in volts across the drift region, and td the time
the ion spends traveling the distance L in seconds. Ion
mobilities depend on temperature and pressure. These
temperature and pressure effects are normalized to standard
conditions to compare values of K in different laboratories
through the use of the reduced mobility constant
(K0,c m
2V
−1s
−1):
K0 ¼ K
P
760
273
T
ð2Þ
where P is the pressure in the drift region in Torr and T the
buffer gas temperature in Kelvin [24]. K0 values are
constant for every compound in a specific buffer gas. A
collection of reduced mobility values from ambient pres-
sure ion mobility spectrometry was published in 1986 [25].
Over-the-counter drugs have been analyzed by IMS-MS
using a handheld mobility spectrometer with a radioactive
source by characterizing the vapors produced through
warming the pharmaceutical solids in air. Acetaminophen,
brompheniramine, chlorpheniramine, pseudoephedrine,
phenylpropanolamine, acetyl salicylic acid, and caffeine
were determined using this method [26]. Eckers et al. used
IMS coupled to liquid chromatography/mass spectrometry
to improve the separation of drug-related materials from
excipients such as polyethylene glycols (PEGs) that make
difficult the detection of trace level impurities in drugs [27].
Budimir et al. analyzed pharmaceutical formulations
using atmospheric pressure ion mobility spectrometry
combined with liquid chromatography and nano-
electrospray ionization. A beta blocker (timolol), antide-
pressant (paroxetine), analgesic (paracetamol), and opiate
(codeine) preparations were studied [28]. Kent et al. found
IMS to be an ultra-fast alternative to HPLC for the
validation of cleaning verification in the pharmaceutical
industry. IMS exceeded all validation requirements for
specificity, precision, linearity, LOQ/LOD, accuracy, stabil-
ity, and speed. Using IMS, the sample analysis portion of
the method validation was approximately eight times faster
than for HPLC to determine residual diphenhydramine on
stainless steel surfaces [29]. Weston et al. [30], using IMS-
time-of-flight MS coupled with desorption electrospray
ionization (DESI) sample introduction, analyzed several
prescription and over-the counter drugs (OTC) drugs
including an antiseptic cream (chlorhexidine), Paracetamol
(acetaminophen), Zantac (ranitidine), and a nicotine-
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ceutical applications of ion mobility spectrometry [9] includes
an ample listing of pharmaceutical compounds identified by
IMS with reduced mobilities, ionic species, and methods
used to identify the compounds. However, none of the over-
the-counter drugs analyzed in the present work is reported in
that review.
Atmospheric pressure electrospray ionization ion mobil-
ity spectrometry (ESI-IMS) may offer a detection method
for the low cost, fast, and sensitive analysis of pharmaceu-
tical formulations and foods due to its rapid monitoring and
high-resolution potential. This method may be an alterna-
tive to slow and expensive methods such as chromatogra-
phy or inaccurate methods such as TOC. Therefore, the
specific objectives of this investigation were to establish if
IMS had the capability for the fast and sensitive qualitative
determination of active ingredients and additives in com-
plex OTC drug formulations and beverages.
Experimental section
Instrument An electrospray-ionization atmospheric-pressure
ion mobility spectrometer coupled to a quadrupole mass
spectrometer (Fig. 1) was used in this work.
The IMS instrument was built at Washington State
University, and a complete description and schematics
can be found in previous publications [31]. The mobility
spectrometer included an electrospray source and a drift
tube. The drift tube consisted of a reaction (desolvation)
region, an ion gate, and a drift region. Both desolvation and
drift region had alternating stainless steel rings, separated
by ceramic insulating rings. The metal rings were con-
nected in series by high temperature resistors (Caddock
Electronics Inc., Riverside, CA, ±1%). The resistors were
0.5 Ω for the desolvation region and 1 MΩ for the drift
region. The drift and desolvation region were 25 and
7.5 cm long, respectively, with an I.D. of 50 mm. A 432 V
cm
−1 electric field was created in the drift tube when
10,800 V were applied to the first ring [32].
The ion gate, which pulsed the ions into the drift region,
was a Bradbury-Nielsen-type. It was made of two series of
forty 75-μm parallel Alloy-46 stainless steel wires (Cal-
ifornia Fine Wire Co., Grove Beach, CA) 0.6 mm apart.
The wires were biased to a potential, creating an orthogonal
field relative to the drift field to stop the ions from passing
into the drift tube. The closure potential was 40 V higher
for one set of wires (positive wires) and 40 V lower for the
other set (negative wires). Positive and negative wires were
alternated in the gate. This closure voltage was removed for
100 µs so that a narrow pulse of ions entered the drift
region. In the first ring of the desolvation region, there was
an electrospray (ESI) target screen made out of 2-mm
stainless steel mesh with a 0.5-cm round orifice in the
center. To help desolvate the ions created by electrospray,
hot N2 gas was introduced as a countercurrent through a
stainless-steel tube at the end of the drift tube at a flow rate
of 0.9 L/min. The buffer gas was heated by passing it
through a 2-m long stainless-steel tube wound inside a
heated aluminum block (Fig. 1). The mobility spectrometer
was operated at atmospheric pressure (690–710 Torr in
Pullman, WA).
Regular parameters used to operate the mobility spec-
trometer were: reaction region length, 7.5 cm; drift tube
length, 25.0 cm; voltage at the first ring, 12.12 kV; voltage
at the gate, 10.80 kV; drift field, 432 V/cm; gate closure
potential, ±40 V; gate pulse width, 0.1 ms; scan time,
35 ms; pressure, 690–710 Torr; buffer gas, nitrogen; buffer
gas temperature, 150±2°C; buffer gas flow, 0.9 lmin
−1
(Table 1).
The mass spectrometer used in this investigation was an
ABB Extrel (Pittsburgh, PA) 150-QC quadrupole
(0–4,000 amu). The software, electronics, and detector of
this instrument were recently upgraded. The electron
multiplier detector signal of the mass spectrometer was
amplified and sent to the data acquisition systems by a
Keithley model 427 amplifier (Keithley Instruments,
Cleveland, OH). The mass spectrometer was run by Merlin
software (version 3.0, ABB Extrel, Pittsburgh, PA), which
collected the mass spectral data. The IMS data was
collected by custom-made LabView software (National
Instruments, Austin, TX), which controlled the ion gate.
The electronics for IMS data acquisition and gate control
were built at WSU [33].
Spectra were acquired in IMS, SIM-IMS, and mass
spectrometry modes. In SIM-IMS mode (single ion mon-
itoring), the mass spectrometer voltages are set so that only
Fig. 1 Instrument. Sketch of the atmospheric pressure ion mobility-
quadrupole mass spectrometer
Int. J. Ion Mobil. Spec. (2009) 12:91–102 93ions of a given mass to charge ratio or a range of ions are
detected. These settings avoid interference of other ions
when determining a specific compound, and mobility
spectra of a specific ion or ions are collected; in IMS
mode, the mass spectrometer is operated in RF only mode
so that ions are pulsed into the drift region, and enter the
mass spectrometer, where they are all detected without
scanning; the mobility spectrum of all ions is collected in
this mode. In mass spectrometry mode, there is no pulsing
of the ions; all ions continuously enter the mass spectrom-
eter, and mass spectra are obtained; the ion mobility
spectrometer is used as a desolvation region, especially
when ESI is in use.
Materials and reagents Tetrabutylammonium (TBA) chlo-
ride, 2,4-dimethylpyridine (2,4-lutidine), and 2,6-di-tert-
butyl pyridine (DTBP) (ACS reagent grade, ≥98% purity),
purchased from Sigma Aldrich Chemical Co. (Milwaukee,
WI), were used as chemical standards. Several over-the-
counter drugs and energetic beverages were selected based
on their popularity and availability. The drugs were chosen
among pain relievers, antihistamines, cough suppressants,
nutritional supplements, laxative and antacid medication,
and eye drops. The active ingredients determined in drugs
were acetaminophen, aspartame, bisacodyl, caffeine, dex-
tromethorphan, diphenhydramine, famotidine, glucosamine,
guaifenesin, loratadine, niacin, phenylephrine, pyridoxine,
thiamin, and tetrahydrozoline. Aspartame and caffeine were
determined in beverages. The drugs and beverages were
purchased from local stores.
Sample preparation and introduction Sample preparation
was simple. Liquids and creams were mixed with the ESI
solution, until a homogeneous mixture was obtained, and
diluted. Solid sample preparation consisted in dissolving the
whole pill, including the coating; solid samples were placed
in a glass vial and shacked overnight in the ESI solution (4.75
H2O:4.75 methanol:0.5 acetic acid). Acetic acid was used to
improve protonation. The clear supernatant was diluted to
0.5 mM in the case of samples with one active ingredient; in
the case of samples with multiple active ingredients, the
solutions were diluted until the less concentrated component
reached a 10-µM concentration.
The chemical standards (TBA ions, 2,4-lutidine, and
DTBP) were prepared in the ESI solvent at a concentration
of 50 µM. Liquid samples or solvent (ESI solution) were
injected using 250-µl syringes by electrospray ionization
(ESI) at a flow rate of 3 µl min
−1 into 40-cm long, 100-µm
ID capillaries. These capillaries were connected through
stainless steel unions (Valco, Houston, TX) to 50-µm ID
capillaries. The end of these capillaries was placed in the
center of the target screen in the first ring of the mobility
spectrometer. To produce positive ions, the metallic union
received a high voltage of 15.6 kV with a 3.5 kV bias with
respect to the first ring at the entrance of the mobility
spectrometer.
Resolving power Resolving power is an indication of
separation efficiency and can be calculated in IMS by:
R ¼ td=w ð3Þ
where td is the drift time of the ion of interest and w is the
temporal peak width measured at half-height [34]. Regard-
less of its resolving power, an instrument cannot separate
two compounds with identical drift times. R values can be
changed in IMS by operating at high electric fields, but
with the undesirable effect of operating the mobility
spectrometer in a region where mobility depends on voltage
(where Eq. 1 is no longer valid).
Calibration and identification of analytes All analytes were
detected as M·H
+ ions, and were identified by mass
spectrometry; their m/z ratio in mass spectrometry was
compared to the molecular weight of their protonated
molecules or clusters. Analytes were further identified by
comparing their reduced mobilities with values reported in
the literature. IMS peak identification was confirmed by
SIM-IMS. The mobility scale was adjusted following the
method of Eiceman et al. [35], who recommend correcting
reduced mobilities by comparing with standards:
K0 unknown ðÞ
K0 standard ðÞ
¼
td standard ðÞ
td unknown ðÞ
ð4Þ
where K0 is the reduced mobility in cm
2V
−1s
−1 and td is the
drift time in ms. This method accounts for errors in
measuring instrumental parameters and eliminates the need
Table 1 ESI-APIMS operating conditions summary
Parameter Settings
Reaction region length 7.5 cm
Drift region length 25.0 cm
ESI voltage 15.6 kV
Voltage at first ring 12.12 kV
ESI flow 180µl hr
−1
Drift tube potential 10.80±0.01 kV
Gate closure potential ±40 V
Gate pulse width 0.1 ms
Scan time 35 ms
Buffer gas Nitrogen
Buffer gas temperature 150±2°C
Buffer gas flow 900 ml min
−1
Pressure 690–700 Torr
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are common standards used to calibrate the reduced
mobility scale [35].
Results and discussions
Figures 2, 3, 4, and 5 show spectra of the rapid analysis of
over-the-counter drugs and beverages obtained by ion
mobility spectrometry. These samples were electrosprayed
directly into the ambient pressure mobility spectrometer
and separated and detected within 9 s.
Single-ingredient over-the-counter drugs
Figure 2 shows the mass and mobility spectra of over-the-
counter (OTC) drugs that comprise a single active ingredi-
ent. Figure 2.1 displays the spectra of the sample Claritin
(Claritin®, Schering, Memphis, TN). The mobility spec-
trum of the sample Claritin in Fig. 2.1a was generated by
operating the quadrupole mass spectrometer in IMS mode.
In this mode, all the ions pass through the mass
spectrometer and are detected by the ion multiplier; this
mode of operation yields the ion mobility spectra of all the
ions in the sample, the total ion mobility spectrum. Claritin
is an antihistaminic medication for treating allergies,
favored over other antihistaminic formulations by its non-
sedating properties (http://Encyclopedia Britannica.
Accessed on May 12, 2009). The electrosprayed solution
of this sample produced a simple ion mobility spectrum
with only a single peak, which occurred at a drift time of
33.5 ms. The ion species present in the mobility spectrum
corresponded to the protonated peak of the pharmaceutical
loratadine (C22H23ClN2O2), the active ingredient of Clar-
itin. A K0 value of 1.04 cm
2V
−1s
−1 was calculated for
loratadine using Eq. 4. Other ions from the solvent occurred
in the spectrum at drift times shorter than 20 ms (not
shown). 250 mobility measurements were averaged to
obtain every mobility spectrum, which represents an
analysis time below 9 s. In Figure 2.1b, the mass spectrum
of the sample Claritin produced a primary peak at m/z
383.9. This is the protonated molecule of loratadine, with a
molecular weight of 382.9 gmol
−1. 500 scans were
averaged to obtain the mass spectra presented in
Figure 2.1b. Because loratadine is an amine, it has a strong
response in positive mode IMS, producing a single product
ion peak through proton transfer reactions with the ions
produced from the electrospray process. To ensure that the
mobility peak at 33.5 ms was the peak at mass 383.9, the
mass spectrometer was operated in single ion monitoring
mode (SIM) in which only the m/z 383.9 peak was
monitored; more specifically, a range of ± 1 Da was
scanned around the MS peak (from 382.9 to 384.9). In SIM
mode, the ion of interest is monitored without the
interference of other ions, increasing the signal to noise
ratio. When the mass spectrometer was operated in SIM
mode, the ion mobility spectrum obtained looked similar to
Fig. 2 Mobility (a) and mass
spectra (b) of single-ingredient
drugs. 2.1 Spectra of an antihis-
taminic medication (Claritin®,
Schering, Memphis, TN) show-
ing the protonated peaks of
loratadine (382.9 gmol
−1)a t
33.5 ms and m/z 383.9. 2.2
Spectra of a joint nutritional
supplement (Spring Valley®,
Schiff, Salt Lake City, UT)
showing the protonated peaks of
glucosamine (179.2 gmol
−1)a t
23.1 ms and m/z 180.2. 2.3
Spectra of eye drops (Eyelieve®,
Orallabs, Memphis, TN) show-
ing the protonated peaks of
tetrahydrozoline (200.3 gmol
−1)
at 24.5 ms and m/z 201.3; the
peak at m/z 224.3 and 26 ms
may be the sodiated adduct of
tetrahydrozoline. Mobility peaks
were identified by SIM-IMS;
mobility and mass spectra were
averaged 250 and 500 times,
respectively
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at 33.5 ms was the protonated molecule of loratadine.
Figure 2.2 presents the spectra of a joint nutritional
supplement (Spring Valley®, Schiff, Salt Lake City, UT),
whose active ingredient is glucosamine. Glucosamine is an
amino sugar, precursor in the biosynthesis of glycosylated
proteins and lipids, commonly used as a treatment for
osteoarthritis (http://Encyclopedia Britannica. Accessed on
May 12, 2009). Figure 2.2a shows the total ion mobility
spectrum of the nutritional supplement. The spectrum,
produced by operating the quadrupole mass spectrometer
in IMS mode, shows four peaks at 23.1, 17.0, 15.6, and
14.2 ms. The peak at 23.1 ms is the protonated peak of
glucosamine (C6H13NO5), for which a K0 value of
1.54 cm
2V
−1s
−1was calculated. The three peaks at lower
drift times correspond to reactant ions or other components
of the drug. The mass spectrum of the joint nutritional
supplement in Fig. 2.2b displayed peaks at m/z 198.2,
180.2, 91.1, 55.1, and 37.1. The protonated peak of
glucosamine occurred at m/z 180.2 (molecular weight of
glucosamine = 179.2 gmol
−1), and a peak of the water
cluster of glucosamine occurred at m/z 198.2. The peaks at
lower masses correspond to reactant ions; m/z 55.1 and
37.1 can be assigned to (H3O)3H
+ and (H3O)2H
+, respec-
tively. The assignment of the peak at 23.1 ms to the
protonated peak of glucosamine was done by operating the
mass spectrometer in SIM mode and scanning m/z 180.2±
1. In SIM mode, only the peak at 23.1 ms was obtained in
the mobility spectrum. Also using SIM, the peak at 14.2 ms
w a sa s s i g n e dt o( H 3O)nH
+. The joint supplement
medication contained another active ingredient, chondroi-
tin, which is a sulfated chain of a variable number
(approximately 100) of alternating glucuronic acid and N-
acetylgalactosamine sugars. This component, important in
the structure of cartilage, could not be detected because it
comprises many chains of different lengths and molecular
weights.
Figure 2.3 includes the mobility and mass spectra of a
sample of eye drops (Eyelieve®, Orallabs, Memphis, TN).
The active ingredient of Eyelieve is tetrahydrozoline, which
constricts the conjunctival blood vessels to relieve the
redness of the eye caused by minor ocular irritants.
Tetrahydrozoline (Fig. 2.3a) produced peaks in the mobility
spectrum at 24.5 ms and 25.8 ms. In the mass spectrum in
Figure 2.3b, the protonated peak of tetrahydrozoline
(C13H16N2, molecular weight = 200.3 gmol
−1) occurred at
m/z 201.3; other peak at m/z 224.3 can be assigned to the
sodiated adduct of tetrahydrozoline; additional peaks at m/z
91.1, 73.1, 60.6, 37.1, and other small peaks below m/z 150
can be assigned to the reactant ions; these peaks are not
shown in the mobility spectrum because they occur at drift
times below 20 ms. Operating the mass spectrometer in
SIM mode by selecting the peak at m/z 201.3, the peak at
24.5 was obtained, for which this mobility peak was
assigned to the protonated peak of tetrahydrozoline. A K0
value of 1.42 cm
2V
−1s
−1 was calculated for this peak. The
mobility peak at 25.8 ms was assigned to the sodiated
adduct of tetrahydrozoline at m/z 224.3 using SIM mode.
A generic laxative medication (Women’s Laxative,
Rite Aid, Harrisburg, PA) and a generic antacid
medication (Acid Reducer, Rite Aid, Harrisburg, PA)
were also analyzed (spectra not shown). The active
ingredient of the laxative medication was bisacodyl
(C22H19NO4, molecular weight = 361.4 gmol
−1), which
is typically prescribed for relief of constipation and for
management of neurogenic bowel dysfunction. The
laxative medication sample yielded a protonated peak
in the mass spectrum at m/z 362.4. Selecting this m/z
in SIM mode, a peak at 35.4 ms was obtained for the
protonated peak of bisacodyl, corresponding to a K0
value of 0.98 cm
2V
−1s
−1. Famotidine (C8H15N7O2S3,
337.4 gmol
−1), the active ingredient of the antacid
Fig. 3 Mobility (a) and mass spectra (b) of two-ingredient drugs. 3.1
Spectra of a migraine medication (Excedrin®, Novartis) showing the
protonated peaks of acetaminophen (151.1 gmol
−1) at 21.0 ms and m/
z 152.1 and caffeine (194.2 gmol
−1) at 23.3 ms and m/z 195.2; acetyl
salicylic acid, another component of the drug, must be detected in the
negative mode. 3.2 Spectra of a cough syrup (Tussin DM Assured)
showing the protonated peaks of guaifenesin (198.2 gmol
−1)a t
23.8 ms and m/z 199.2 and dextromethorphan (271.4 gmol
−1)a t
29.3 ms and m/z 272.4; a possible water cluster of guaifenesin was
visible at 25 ms and m/z 217.2 and a sodium adduct at 25.6 ms and m/
z 222.2. Mobility peaks were identified by SIM-IMS; mobility and
mass spectra were averaged 250 and 500 times, respectively
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production, and it is commonly used in the treatment of
gastric ulcer (http://Encyclopedia Britannica. Accessed on
May 12, 2009). Famotidine produced a strong mass peak
at m/z 338.4. In the IMS mode, a single peak for the
antacid medication occurred at 30.7 ms; this mobility
peak was identified by SIM-IMS as the protonated
peak of famotidine, and a K0 value of 1.15 cm
2V
−1s
−1
was calculated for it.
Two-ingredient OTC drugs
Figure 3 shows the mass and mobility spectra of common
OTC drugs composed of two-ingredients. Figure 3.1
includes the mobility and mass spectra of a migraine
medication (Excedrin®, Novartis) containing the active
components caffeine and acetaminophen. Caffeine is an
alkaloid that acts as a psychoactive stimulant drug and a
mild diuretic; acetaminophen is a widely used over-the-
counter analgesic and antipyretic, and is a major ingredient
in numerous cold and flu remedies (http://Encyclopedia
Britannica. Accessed on May 12, 2009). The mobility
spectrum for the migraine medication produced two strong
peaks at 23.3 ms and at 21.0 ms (Fig. 3.1a). SIM-IMS
analysis allowed the identification of the peaks as the
product ions of caffeine and acetaminophen, for which
respective K0 values of 1.66 and 1.53 cm
2V
−1s
−1 were
calculated. The mass spectrum in Fig. 3.1b shows the
protonated peaks of caffeine (C8H10N4O2, 194.2 gmol
−1)
and acetaminophen (C8H9NO2, 151.1 gmol
−1) occurring at
Fig. 4 Mobility (a) and mass spectra (b) of three-ingredient drugs.
This figure demonstrates the rapid IMS separation and identification
of complex formulations. 4.1 Spectra of an allergy and sinus headache
medication (Benadryl®, Pfizer, Morris Plains, NJ) showing the
protonated peaks of acetaminophen (151.1 gmol
−1) at 21.6 ms and
m/z 152.1, phenylephrine (167.2 gmol
−1) at 22.6 ms and m/z 168.2,
and diphenhydramine (255.4 gmol
−1) at 27.9 ms and m/z 256.4. 4.2
Spectra of a vitamin B supplement (People’s Choice, Mason Vitamins,
Miami Lakes, FL) showing the protonated peaks of niacin (123.1 g
mol
−1) at 19.9 ms and m/z 124.1, pyridoxine (169.2 gmol
−1)a t
22.1 ms and m/z 170.2, and thiamin (265.4 gmol
−1) at 28.3 ms and m/
z 266.4. 4.3 Spectra of a cold medication (Rite Aid, Camp Hill, PA)
showing the protonated peaks of acetaminophen at 21.0 ms and m/z
152.1, phenylephrine at 23.1 ms and m/z 168.2, and dextromethor-
phan (271.4 gmol
−1) at 28.5 ms and m/z 272.4. Mobility peaks were
identified by SIM-IMS; mobility and mass spectra were averaged 250
and 500 times, respectively
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another component of the drug, must be detected in the
negative mode, which was not set up in our instrument at
the time the experiments were performed.
The mobility and mass spectra of a cough syrup (Tussin
DM Assured) are presented in Fig. 3.2. Guaifenesin and
dextromethorphan were the active ingredients of the drug.
Guaifenesin (C10H14O4, 198.2 gmol
−1) is an expectorant
drug used also in the treatment of asthma, fibromyalgia, and
gout, and as analgesic; dextromethorphan (C18H25NO,
271.4 gmol
−1) is an antitussive drug, also used as a pain
reliever (http://Encyclopedia Britannica. Accessed on May
12, 2009). The mobility spectrum in Fig. 3.2a shows peaks
at 23.8 ms (protonated peak of guaifenesin), 25.0 ms (water
cluster of guaifenesin), 25.6 ms (sodium adduct of
guaifenesin), and 29.3 ms (protonated peak of dextro-
methorphan). Guaifenesin and dextromethorphan occurred
at m/z 199.2 and 272.4, respectively, in the mass spectrum
(Fig. 3.2b). Two additional peaks were observed in the
mass spectrum corresponding to the water cluster of
guaifenesin at m/z 217.2 and its sodium adduct at m/z
222.2. K0 values of 1.51 and 1.22 cm
2V
−1s
−1 were obtained
for guaifenesin and dextromethorphan, respectively.
Three-ingredient OTC drugs
Figure 4 illustrates the mobility and mass spectra of OTC
drugs containing three-ingredients, demonstrating the rapid
IMS separation and identification of complex over-the-
counter (OTC) formulations. The spectra of a generic
allergy and sinus headache medication (Benadryl®, Pfizer,
Morris Plains, NJ) composed of acetaminophen, phenyl-
ephrine, and diphenhydramine is shown in Fig. 4.1.
Phenylephrine, now the most common OTC decongestant
in the United States, relieve swelling of the nasal mucosa
accompanying such conditions as the common cold and hay
fever; and diphenhydramine is a synthetic antihistamine
used in the treatment of various conditions including hay
fever, acute skin reactions (such as hives), contact derma-
titis (such as from poison ivy), and motion sickness (http://
Encyclopedia Britannica. Accessed on May 12, 2009). The
mobility peaks of the active ingredients of this drug,
assigned by operating the instrument in SIM-ESI mode,
occurred at 21.6 ms (acetaminophen), 22.6 ms (phenyleph-
rine), and 27.9 ms (diphenhydramine) (Fig. 4.1a). The
protonated peaks of acetaminophen (151.1 gmol
−1), phen-
ylephrine (C9H13NO2, 167.2 gmol
−1), and diphenhydra-
Fig. 5 Mobility (a) and mass
spectra (b) of energetic bever-
ages and standard solutions. 5.1
Spectra of Diet coke showing
the protonated peaks of caffeine
(194.2 gmol
−1) at 23.2 ms and
m/z 195.2 and aspartame
(294.3 gmol
−1) at 29.5 ms and
m/z 295.3. 5.2 Standard solution
of caffeine and aspartame
(500 μM) showing the proton-
ated peaks of caffeine at 23.0 ms
and m/z 195.2 and aspartame at
29.4 ms and m/z 295.3. The
peaks at m/z 213.2 and 313.3
are most probably water clus-
ters. 5.3 Spectra of an antioxi-
dant water (Snapple®) showing
the protonated peaks of niacin
(123.1 gmol
−1) at 19.8 ms and
124.1 and caffeine at 23.0 ms
and m/z 195.2. Mobility peaks
were identified by SIM-IMS;
mobility and mass spectra were
averaged 250 and 500 times,
respectively
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−1), the strongest peaks in the
mass spectrum, are shown in Fig. 4.1b; these peaks
occurred at m/z 152.1, 168.2, and 256.4, respectively. K0
values calculated for these compounds were: 1.66 (acet-
aminophen), 1.53 (phenylephrine), and 1.23 cm
2V
−1s
−1
(diphenhydramine). Benadryl® contained 16 inactive ingre-
dients, comprising waxes, tar dyes, polymers, and carbohy-
drates, which gave the mobility spectrum a noisy
appearance.
Figure 4.2 illustrates the mobility and mass spectra of a
generic vitamin B supplement (People’s Choice, Mason
Vitamins, Miami Lakes, FL). The spectra included the
protonated peaks of niacin (C6H5NO2, 123.1 gmol
−1),
pyridoxine (C8H11NO3, 169.2 gmol
−1), and thiamin
(C12H17N4OS
+, 265.4 gmol
−1). Niacin (vitamin B3 or
nicotinic acid) prevents the deficiency disease pellagra;
pyridoxine (vitamin B6) assists amino acid metabolism, as
well as promoting red blood cell production; and thiamin
(thiamine or vitamin B1), is necessary for carbohydrate
metabolism in both plants and animal (http://Encyclopedia
Britannica. Accessed on May 12, 2009). The mobility
spectrum of the vitamin supplement in Fig. 4.2a shows the
protonated peaks of niacin (19.9 ms), pyridoxine (22.1 ms),
and thiamin (28.3 ms). These peaks were assigned
operating the instrument in SIM-ESI mode. The mass
spectrum of the supplement is displayed in Fig. 4.2b, and
included the protonated peaks of niacin (m/z 124.1),
pyridoxine (m/z 170.2), and thiamin (m/z 266.4). Ribofla-
vin and folic acid, other B vitamins present in the
supplement, were not seen in the mass spectrum perhaps
due to their low concentration. K0 values calculated for
these compounds were: 1.80 (niacin), 1.62 (pyridoxine),
and 1.26 cm
2V
−1s
−1 (thiamin).
The mobility and mass data generated in the analysis
of a generic cold medication (Rite Aid, Camp Hill, PA)
i sp r e s e n t e di nF i g .4.3. This medication contained
acetaminophen, phenylephrine, and dextromethorphan.
Dextromethorphan is an antitussive drug and has been
used also for pain relief (http://Encyclopedia Britannica.
Accessed on May 12, 2009). The mobility spectrum of
the cold medication (Fig. 4.3a) shows the protonated
peaks of acetaminophen, phenylephrine, and dextrome-
thorphan occurring at 21.0 ms, 23.1 ms, and 28.5 ms,
respectively. SIM-IMS was used to identify the peaks. In
the mass spectrum, the protonated peaks of the active
ingredients occurred at m/z 152.1 (acetaminophen), m/z
168.2 (phenylephrine), and m/z 272.4 (dextromethor-
phan) in the cold medication (Fig. 4.3b). K0 values
calculated for these pharmaceuticals were: 1.66 (acet-
aminophen), 1.53 (phenylephrine), and 1.22 cm
2V
−1s
−1
(dextromethorphan).
In general, the active ingredients in OTC drugs for all
the medications analyzed had one or more heteroatoms,
such as nitrogen and oxygen, which imparted a large
proton affinity to these ingredients. This high proton
affinity allowed the active ingredients of OTC drugs to be
ionized largely by proton transfer reactions with reactant
ions in the electrospray process. This efficient ionization
of the active ingredients produced clean mobility and
mass spectra and sharp identifiable peaks with few
exceptions. In all samples analyzed, the active ingredients
and their hydrated or sodiated clusters produced the
strongest peaks in the mass spectrum. All active ingre-
dients were identified in the mobility spectra by SIM-IMS
in spite of the complexity of the formulation, with few
exceptions.
Analyses of beverages
The soda drink and bottled water industry in the US
includes about 3,000 companies that manufacture and
distribute beverages, with combined annual US revenue
of $70 billion (http://www.scribd.com.A c c e s s e do nM a y
12, 2009). The large production of beverages requires
rapid and low-cost technologies for their chemical analysis.
Figure 5 shows the mass and mobility spectra of energetic
beverages and standard solutions of caffeine and aspar-
tame. Caffeine (194.2 gmol
−1) and aspartame (C14H18N2O5,
294.3 gmol
−1) were determined in Diet coke and an anti-
oxidant water. Aspartame is an artificial, non-saccharide
sweetener, 180 times sweeter than sugar, without its high
energy value. The IMS protonated peaks of caffeine and
aspartame in Diet coke are shown in Fig. 5.1a; caffeine
occurred at 23.2 ms and aspartame at 29.5 ms, as single
peaks in the mobility spectrum. The peaks were assigned
operating the instrument in SIM-IMS mode. Other peaks
occurred at higher mobilities, probably the reactant ions
and ions from other components in the beverage. The mass
spectrum of Diet Coke is presented in Fig. 5.1b, showing
the protonated peaks of caffeine at m/z 195.2 and
aspartame at m/z 295.3. The baseline increased toward
higher mobilities in the IMS spectrum and toward lower
masses in the mass spectrum, probably due to the
complexity of the sample, Diet Coke, which is a blend of
colors, flavors, and other components.
Figure 5.2 presents the mobility and mass spectra of a
standard solution of caffeine and aspartame. The mobility
spectrum in Fig. 5.2a included the protonated peaks of
caffeine at 23.0 ms and aspartame at 29.4 ms in a 500-µM
standard solution, identified operating the instrument in the
SIM-IMS mode. Figure 5.2b presents the mass spectrum of
the standard solution showing the protonated peaks of
caffeine at m/z 195.2 and aspartame at m/z 295.3. The
peaks at m/z 213.2 and 313.3 were probably water clusters
of caffeine and aspartame. These peaks can also be seen,
although less clearly, in Fig. 5.1b.
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of a sample of antioxidant water (Snapple®). In Fig. 5.3a,
the protonated peaks of niacin (123.1 gmol
−1)a n d
caffeine, identified by SIM-IMS, occurred at 19.8 ms at
23.0 ms, respectively, in the mobility spectrum of the
beverage. The mass spectrum of this water in Fig. 5.3b
produced the protonated peaks of niacin (123.1 gmol
−1)
at m/z 124.1 and caffeine at m/z 195.2. Peaks of unknown
ingredients ocurred at m/z 219.3 and 141.1 in the mass
spectrum and at 22.0, 21.5, and 21.1 ms in the mobility
spectrum. K0 values calculated in both beverages and
the standards were 1.53 for caffeine and 1.16 cm
2V
−1s
−1
for aspartame.
These spectra revealed the capabilities of IMS for the
rapid separation and identification of active ingredients in
complex over-the-counter drugs and food additives in
beverages. Some of the OTC drugs and beverages
contained up to 18 ingredients several of which were
complex mixtures of lipids, polymers, and carbohydrates.
Moreover, the concentrations of the ingredients deter-
mined were dissimilar with differences up to approxi-
mately 500-fold in some cases. However, the spectra
obtained in most cases were clean, and the ingredients
were identified easily. This IMS selectivity is based on the
high proton affinity of active ingredients of OTC drugs
and food additives due to their nitrogen and oxygen
content. In the analysis of three-ingredients drugs,
brompheniramine and chlorpheniramine could not be
detected in the mobility spectra of two products probably
due to ionization competition of other active ingredients
present at higher concentrations. However, the protonated
peaks of these two compounds were visible in the mass
spectrum, although with a low intensity.
A common method to validate results in IMS is
through comparison of reduced mobilities with literature
values. Reduced mobilities of active ingredients in OTC
drugs and food additives and their concentrations in the
solution analyzed are presented in Table 2. Three reduced
mobilities of active ingredients were found in the literature
out of 15 ingredients determined: 1.67 (acetaminophen),
1.54 (caffeine), and 1.55 cm
2V
−1s
−1 (glucosamine). The
reduced mobilities for these compounds obtained in this
work were: 1.66 (acetaminophen), 1.53 (caffeine), and
1.54 cm
2V
−1s
−1 (glucosamine); these reduced mobilities
Table 2 Reduced mobilities of active ingredients in OTC drugs and food additives and their concentrations in the solution analyzed
Compound K0,c m
2V
−1s
−1 Concentration, mM
This work Literature values
Acetaminophen 1.66 1.67
a (1) 44, (3) 4.8, (4) 33
Aspartame 1.16 (12) 0.12
Bisacodyl 0.98 (7) 0.5
Caffeine 1.53 1.54
a 1.54
b (4) 0.067, (12) 0.067, (13) 0.05, (14) 0.05
Dextromethorphan 1.22 (3) 0.058, (5) 0.057
Diphenhydramine 1.23 (1) 0.87, (6) 0.017
Famotidine 1.15 (11) 0.50
Glucosamine 1.54 1.55
c 1.37
d (8) 0.5
Guaifenesin 1.51 (5) 1.0
Loratadine 1.04 (9) 0.5
Niacin 1.80 (2)
Phenylephrine 1.53 (1) 0.50, (3) 0.050
Pyridoxine 1.62 (2)
Tetrahydrozoline 1.42 (10) 0.05
Thiamin 1.26 (2)
a[36];
b[37];
c[38];
d[39]; (1) Allergy and sinus headache medication (Benadryl®, Pfizer, Morris Plains, NJ). (2) Vitamin B supplement (People’s
Choice, Mason Vitamins, Miami Lakes, FL). (3) Cold medication (Rite Aid, Camp Hill, PA). (4) Migraine medication (Excedrin®, Novartis). (5)
Cough syrup (Tussin DM Assured). (6) Allergy drug (Allergy liquid, Assured, Bio-Pharm, Levittown, PA). (7) Laxative medication (Women’s
Laxative, Rite Aid, Harrisburg, PA). (8) Joint nutritional supplement (Spring Valley®, Schiff, Salt Lake City, UT). (9) Antihistaminic medication
(Claritin®, Schering, Memphis, TN). (10) Eye drops (Eyelieve®, Orallabs, Memphis, TN). (11) Antacid medication (Acid Reducer, Rite Aid,
Harrisburg, PA); (12) Diet coke. (13) Antioxidant water (Snapple®). (14) Orange Twist (Eating Right®). The reproducibility of the values in this
table was <2%, calculated as the relative standard deviation (RSD) of the reduced mobilities of five different samples analyzed on different days.
The repeatability of the values in this table was <0.5%, calculated as the RSD of the reduced mobilities of five or more consecutive analyses (250
averages each) of the sample
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literature values, which was within the maximum 2% of
accepted variance for data obtained in different laborato-
ries. All other active ingredients in Table 2 were first-time
determined by IMS, or their reduced mobilities were not
reported when they were determined. A mass-mobility
correlation coefficient of −0.97 was found for the
ingredients in Table 2, which indicates the increasing
size, and decreasing mobility, as the molecular weight
increased.
Resolving power and signal to noise ratio
A high resolving power is a desirable feature of analytical
techniques intended to separate complex OTC drugs
comprising several active and inactive ingredients. A high
resolving power produces sharp analyte peaks that can be
easily distinguished from peaks of other ingredients in the
mobility spectra. Figure 6 demonstrates the high resolving
powers obtained in SIM-IMS mode when analyzing OTC
drugs and beverages. Resolving powers up to 140 were
obtained with an average of 100. Figure 6 shows these high
resolving powers in the mobility spectra of diphenhydra-
mine in Benadryl® (resolving power 140), aspartame in
Diet Coke® (resolving power 126), and tetrahydrozoline in
Eyelieve® (resolving power 113). These high resolving
powers allowed the resolution of the complex mixtures
analyzed in this work. The signal to noise ratio for these
analysis were 61 for diphenhydramine in Benadryl®, 41 for
aspartame in Diet Coke®, and 20 for tetrahydrozoline in
Eyelieve® at concentrations of 0.87, 0.12, and 0.05 mM,
respectively.
Analysis time
A short analysis time is another desirable feature of
analytical techniques that increases production in the
pharmaceutical and food industries due to rapid cleaning
verification and quality control and lower labor require-
ments. A short analysis time contributes to reduce costs
and increase competitiveness. The number of averages
used to obtain mobility spectra in this investigation was
250; with a scan time of 35–40 ms, instrumental analysis
times below 10 s were obtained. The short duration of
the analyses represents one of the features that translate
into economy in IMS. These short analysis times were
lower than those for HPLC (not including sample
preparation). HPLC is a common analytical technique
for the analysis of over-the counter-drugs and determi-
nation of food additives, but the analysis times are
between 1 and 20 min, and instruments and maintenance
are expensive.
Conclusions
We demonstrated the fast qualitative determination of
active ingredients in over-the-counter drugs and food
additives in beverages without sample pretreatment using
electrospray-ion mobility spectrometry (ESI-IMS). Anal-
ysis times below 10 s were obtained for these samples.
Clear separation and identification of the analyte peaks
were obtained after a simple dissolution step in composite
samples with 10–19 declared ingredients, some of which
were complex mixtures of waxes, carbohydrates, poly-
mers, dyes, and other large molecules. Complex samples
with analyte concentrations down to 17 μMw e r e
analyzed, with other components at higher concentrations,
indicating high selectivity and sensitivity. Resolving
powers up to 140, with an average of 100, allowed
resolution of the complex mixtures analyzed in this work.
The combination of fast detection times, selectivity,
sensitivity, low cost, and easy maintenance of ESI-IMS
instruments makes this technique an attractive alternative
for the qualitative analysis of over-the-counter drugs and
beverages.
Fig. 6 Resolving power. SIM-IMS spectra of drugs and food
additives showing the high resolving powers obtained by IMS. a
Diphenhydramine (Resolving power 140) in the allergy and sinus
headache medication (Benadryl®, Pfizer, Morris Plains, NJ). b
Aspartame (Resolving power 126) in Diet Coke. c Tetrahydrozoline
(Resolving power 113) in eye drops (Eyelieve®, Orallabs, Memphis,
TN). Mobility spectra were averaged 250 times
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